DSX is faster, more user-friendly, and scalable for high-performance computing
The latest version of its flagship quantitative systems toxicology (QST) software for predicting and analysing drug-induced liver injury, DILIsym® version X (DSX) Beta, has been made available by Simulations Plus, Inc., a leading provider of modelling and simulation software and services for pharmaceutical safety and efficacy (DILI).
The DILI-sim Initiative’s Scientific Advisory Board chair, Dr. Paul B. Watkins, stated: “When it comes to correctly anticipating new drug candidates’ liver safety risks, DILIsym has proven to be quite valuable. DSX is a significant advancement since it makes the programme easier to use and significantly speeds up the rate at which it produces results. Pharma, regulators, and academia will be able to use the programme much more widely as a result.”
Dr. Brett Howell, president of the DILIsym Services division, added: “DILIsym is increasingly being used for high impact applications in the safety space. This latest release of DSX, which is the product of very hard work by our software development team, led by our Senior Software Engineer Corey Berry, enhances the speed and user-friendliness of DILIsym forward significantly.”
By estimating the possible DILI risk of novel drug candidates, DILIsym modelling aids in important drug development choices. Additionally, the modelling pinpoints the biochemical processes that a medication-induced DILI causes, allowing for the prediction of particular patient subgroups that are more likely to experience DILI as a result of that drug. In order to avoid the potentially disastrous financial effects of unsuccessful clinical trials or, better yet, to provide assurances that DILI will not be an insurmountable barrier to FDA approval, the information from DILIsym modelling is used to help guide go/no-go decisions on significant drug development projects. The DILI-sim Initiative, a public-private collaboration that has aided in the development of the DILIsym software, has been overseen for the past 12 years by the DILIsym Services division.
Significant DSX revisions include:
- A comprehensive software revamp with server/cloud computing capability, command line and graphical interface choices (HPGL)
- Included are 4 novel example substances with various clinical manifestations:
- PF-04895162 (Generaux 2019)
- Efavirenz
- Anastrozole
- Tamoxifen
- 2 novel SimCohorts with variable sensitivity to liver damage and parameters connected to biomarkers (ALT and bilirubin)
